468 related articles for article (PubMed ID: 27527085)
21. Benzothiazinones mediate killing of Corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall biosynthesis.
Grover S; Alderwick LJ; Mishra AK; Krumbach K; Marienhagen J; Eggeling L; Bhatt A; Besra GS
J Biol Chem; 2014 Feb; 289(9):6177-87. PubMed ID: 24446451
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo antimicrobial activities of a novel piperazine-containing benzothiazinones candidate TZY-5-84 against Mycobacterium tuberculosis.
Guo S; Fu L; Wang B; Chen X; Zhao J; Liu M; Lu Y
Biomed Pharmacother; 2020 Nov; 131():110777. PubMed ID: 33152936
[TBL] [Abstract][Full Text] [Related]
23. Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors.
Whitehurst BC; Young RJ; Burley GA; Cacho M; Torres P; Vela-Gonzalez Del Peral L
Bioorg Med Chem Lett; 2020 Jun; 30(12):127192. PubMed ID: 32312582
[TBL] [Abstract][Full Text] [Related]
24. Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance.
Manina G; Bellinzoni M; Pasca MR; Neres J; Milano A; Ribeiro AL; Buroni S; Skovierová H; Dianišková P; Mikušová K; Marák J; Makarov V; Giganti D; Haouz A; Lucarelli AP; Degiacomi G; Piazza A; Chiarelli LR; De Rossi E; Salina E; Cole ST; Alzari PM; Riccardi G
Mol Microbiol; 2010 Sep; 77(5):1172-85. PubMed ID: 20624223
[TBL] [Abstract][Full Text] [Related]
25. Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis.
Gao C; Peng C; Shi Y; You X; Ran K; Xiong L; Ye TH; Zhang L; Wang N; Zhu Y; Liu K; Zuo W; Yu L; Wei Y
Sci Rep; 2016 Jul; 6():29717. PubMed ID: 27405961
[TBL] [Abstract][Full Text] [Related]
26. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
[TBL] [Abstract][Full Text] [Related]
27. Synthetic molecules as DprE1 inhibitors: A patent review.
Imran M; A S A; Thabet HK; Abida ; Afroz Bakht M
Expert Opin Ther Pat; 2021 Aug; 31(8):759-772. PubMed ID: 33709862
[TBL] [Abstract][Full Text] [Related]
28. Exploring disordered loops in DprE1 provides a functional site to combat drug-resistance in Mycobacterium strains.
Liu J; Dai H; Wang B; Liu H; Tian Z; Zhang Y
Eur J Med Chem; 2022 Jan; 227():113932. PubMed ID: 34700267
[TBL] [Abstract][Full Text] [Related]
29.
Shi J; Lu J; Wen S; Zong Z; Huo F; Luo J; Liang Q; Li Y; Huang H; Pang Y
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150479
[TBL] [Abstract][Full Text] [Related]
30. Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis.
Ribeiro AL; Degiacomi G; Ewann F; Buroni S; Incandela ML; Chiarelli LR; Mori G; Kim J; Contreras-Dominguez M; Park YS; Han SJ; Brodin P; Valentini G; Rizzi M; Riccardi G; Pasca MR
PLoS One; 2011; 6(11):e26675. PubMed ID: 22069462
[TBL] [Abstract][Full Text] [Related]
31. 4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity.
Naik M; Humnabadkar V; Tantry SJ; Panda M; Narayan A; Guptha S; Panduga V; Manjrekar P; Jena LK; Koushik K; Shanbhag G; Jatheendranath S; Manjunatha MR; Gorai G; Bathula C; Rudrapatna S; Achar V; Sharma S; Ambady A; Hegde N; Mahadevaswamy J; Kaur P; Sambandamurthy VK; Awasthy D; Narayan C; Ravishankar S; Madhavapeddi P; Reddy J; Prabhakar K; Saralaya R; Chatterji M; Whiteaker J; McLaughlin B; Chiarelli LR; Riccardi G; Pasca MR; Binda C; Neres J; Dhar N; Signorino-Gelo F; McKinney JD; Ramachandran V; Shandil R; Tommasi R; Iyer PS; Narayanan S; Hosagrahara V; Kavanagh S; Dinesh N; Ghorpade SR
J Med Chem; 2014 Jun; 57(12):5419-34. PubMed ID: 24871036
[TBL] [Abstract][Full Text] [Related]
32. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
Balabon O; Pitta E; Rogacki MK; Meiler E; Casanueva R; Guijarro L; Huss S; Lopez-Roman EM; Santos-Villarejo Á; Augustyns K; Ballell L; Aguirre DB; Bates RH; Cunningham F; Cacho M; Van der Veken P
J Med Chem; 2020 May; 63(10):5367-5386. PubMed ID: 32342688
[TBL] [Abstract][Full Text] [Related]
33. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.
Landge S; Mullick AB; Nagalapur K; Neres J; Subbulakshmi V; Murugan K; Ghosh A; Sadler C; Fellows MD; Humnabadkar V; Mahadevaswamy J; Vachaspati P; Sharma S; Kaur P; Mallya M; Rudrapatna S; Awasthy D; Sambandamurthy VK; Pojer F; Cole ST; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M; Ramachandran V
Bioorg Med Chem; 2015 Dec; 23(24):7694-710. PubMed ID: 26643218
[TBL] [Abstract][Full Text] [Related]
34. Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches.
Dash S; Rathi E; Kumar A; Chawla K; Kini SG
Sci Rep; 2024 May; 14(1):11315. PubMed ID: 38760437
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the development of DprE1 inhibitors using AI/CADD approaches.
Chen K; Xu R; Hu X; Li D; Hou T; Kang Y
Drug Discov Today; 2024 Jun; 29(6):103987. PubMed ID: 38670256
[TBL] [Abstract][Full Text] [Related]
36. Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis.
Piton J; Vocat A; Lupien A; Foo CS; Riabova O; Makarov V; Cole ST
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012754
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities.
Wang P; Batt SM; Wang B; Fu L; Qin R; Lu Y; Li G; Besra GS; Huang H
J Med Chem; 2021 May; 64(9):6241-6261. PubMed ID: 33852302
[TBL] [Abstract][Full Text] [Related]
38. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
[TBL] [Abstract][Full Text] [Related]
39. Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides.
Chikhale R; Menghani S; Babu R; Bansode R; Bhargavi G; Karodia N; Rajasekharan MV; Paradkar A; Khedekar P
Eur J Med Chem; 2015; 96():30-46. PubMed ID: 25874329
[TBL] [Abstract][Full Text] [Related]
40. Decaprenylphosphoryl-β-D-ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis.
Crellin PK; Brammananth R; Coppel RL
PLoS One; 2011 Feb; 6(2):e16869. PubMed ID: 21346818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
